Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
COGT 
Cogent Biosciences Inc (COGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: COGT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 13.85% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 659.19M USD | Price to earnings Ratio - | 1Y Target Price 16.5 |
Price to earnings Ratio - | 1Y Target Price 16.5 | ||
Volume (30-day avg) 1271859 | Beta 0.08 | 52 Weeks Range 5.48 - 12.61 | Updated Date 04/1/2025 |
52 Weeks Range 5.48 - 12.61 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.94 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.78% | Return on Equity (TTM) -99.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 500182021 | Price to Sales(TTM) 1320.63 |
Enterprise Value 500182021 | Price to Sales(TTM) 1320.63 | ||
Enterprise Value to Revenue 925.41 | Enterprise Value to EBITDA -3.89 | Shares Outstanding 113850000 | Shares Floating 69993334 |
Shares Outstanding 113850000 | Shares Floating 69993334 | ||
Percent Insiders 0.16 | Percent Institutions 108.06 |
Analyst Ratings
Rating 4.18 | Target Price 16.8 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cogent Biosciences Inc
Company Overview
History and Background
Cogent Biosciences, Inc. (formerly Plexxikon, Inc.) was founded in 2014 and is based in Cambridge, Massachusetts. The company is focused on developing precision therapies for genetically defined diseases.
Core Business Areas
- Precision Oncology: Development of selective kinase inhibitors targeting specific genetic mutations in cancer, primarily focusing on advanced systemic mastocytosis and gastrointestinal stromal tumors (GIST).
Leadership and Structure
Andrew Robbins (President and CEO), Brad Gray (Chairman). Organized into research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- Bezvercidib: A selective KIT D816V inhibitor being developed for advanced systemic mastocytosis (ASM) and gastrointestinal stromal tumors (GIST). Currently in clinical trials. Market share data unavailable as it is not yet approved. Competitors include Novartis (PKI) with ripretinib.
Market Dynamics
Industry Overview
The precision oncology market is growing rapidly, driven by advancements in genetic sequencing and targeted therapies. High unmet need remains in rare and genetically defined cancers.
Positioning
Cogent Biosciences is positioned as a leader in developing selective kinase inhibitors for genetically defined diseases, particularly focusing on KIT-driven disorders. Their competitive advantage lies in the high selectivity of their drug candidates.
Total Addressable Market (TAM)
The TAM for targeted therapies in ASM and GIST is estimated to be in the billions of dollars. Cogent is positioned to capture a significant share of this market if bezvercidib is approved.
Upturn SWOT Analysis
Strengths
- Highly selective kinase inhibitors
- Strong scientific team
- Focus on genetically defined diseases
- Promising clinical trial results
Weaknesses
- Single lead product
- High cash burn
- Clinical trial risks
- Dependence on regulatory approvals
Opportunities
- Expansion into other genetically defined diseases
- Potential for strategic partnerships
- Favorable regulatory environment for orphan drugs
- Growing awareness of precision oncology
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- NVS
- BLU
Competitive Landscape
Cogent faces competition from established pharmaceutical companies with existing targeted therapies. Cogent's advantage lies in the selectivity and potential efficacy of its novel kinase inhibitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Cogent's historical growth is characterized by the advancement of its lead product candidate through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of bezvercidib. Analyst estimates vary widely.
Recent Initiatives: Advancement of bezvercidib through Phase 2 and Phase 3 clinical trials.
Summary
Cogent Biosciences is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined diseases. The company's lead product candidate, bezvercidib, holds promise for treating ASM and GIST. Key risks include clinical trial failures and competition from established players. Successful development and commercialization of bezvercidib are crucial for Cogent's long-term success.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
TGTX
TG Therapeutics Inc
TGTX
TG Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cogent Biosciences Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2018-03-29 | President, CEO & Director Mr. Andrew R. Robbins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 205 | Website https://www.cogentbio.com |
Full time employees 205 | Website https://www.cogentbio.com | ||
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.